Lilly's diabetes drug shines in study, rival Novo shares slips

Eli Lilly and Co said on Thursday data from a mid-stage trial of a new two-in-one diabetes drug lowered blood sugar and reduced weight in type 2 diabetes patients, hurting shares of arch-rival Novo Nordisk.